drugset / Trial / NCT02970968

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

NCT02970968

Phase 2 Completed 152 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

Timeline

Start
2016-11
Primary completion
2018-11
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule 85 mg Oral

Indications